The 21 Wall Street analysts covering ResMed, Inc. hold a median 12-month price target of $270 — +12.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ResMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Momentum (41): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.2% from it.
Of the 20 most recent actions, 7 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Canaccord Genuity | Downgrade | Hold | — |
| 30 Oct 2026 | Citigroup | Maintains | Neutral | $240 → $270 |
| 30 Oct 2026 | Keybanc | Maintains | Overweight | $267 → $277 |
| 30 Oct 2026 | RBC Capital | Maintains | Outperform | $262 → $288 |
| 30 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $215 → $250 |
| 15 Sept 2026 | RBC Capital | Upgrade | Outperform | — |
| 15 Sept 2026 | RBC Capital | Upgrade | Outperform | $244 → $262 |
| 31 Aug 2026 | Keybanc | Maintains | Overweight | — |
| 31 Aug 2026 | Keybanc | Maintains | Overweight | $255 → $267 |
| 19 Aug 2026 | Rothschild & Co | Initiates | Neutral | — |
| 19 Aug 2026 | Rothschild & Co | Initiates | Neutral | $230 |
| 7 Aug 2026 | Keybanc | Maintains | Overweight | $260 → $255 |
| 7 Aug 2026 | Keybanc | Maintains | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | $233 → $225 |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | $234 → $244 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $225 → $215 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $235 → $220 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, ResMed, Inc. returned −1.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 37% of US stocks
Cheaper than 21% of US stocks
Cheaper than 18% of US stocks
Cheaper than 23% of US stocks
Higher than 43% of US stocks
Higher than 59% of US stocks
Higher than 72% of US stocks
Higher than 89% of US stocks
Higher than 87% of US stocks
Higher than 86% of US stocks
Higher than 97% of US stocks
Higher than 72% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ResMed, Inc. has a market value of $31.9B and an enterprise value of $32.4B.
Revenue in the twelve months to 30 June 2026: $5.7B. The latest quarter grew 5.9% year on year.
Net income over the same four quarters: $1.5B, a 26.9% net margin.
Diluted earnings per share, trailing twelve months: $10.43.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
ResMed, Inc. spent $700.0M on share buybacks and $349.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 20.5×; forward P/E: 17.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.16%, paying out 22% of earnings.
ResMed, Inc. employs 11,370 people — $497K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ResMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha listed RMD among 10 high-quality dividend growth stocks for November 2026, using criteria that included consistent dividend growth, payout ratios below 100%, and stated future-return potential.
Why it matters — The item highlights RMD as a dividend-growth stock in the publication’s screened list.
ResMed reported 7% first-quarter growth in core constant-currency revenue. The excerpt also says patients taking GLP-1 drugs are 11% more likely to start CPAP therapy.
Why it matters — These figures highlight recent revenue growth and a reported association between GLP-1 use and CPAP therapy initiation, both relevant to tracking ResMed.
The article says ResMed’s Q1 revenue and EPS provide a view of performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago figures.
Why it matters — Those comparisons give RMD watchers additional context for assessing quarterly performance beyond revenue and EPS alone.
ResMed reported first-quarter fiscal 2027 earnings and revenue above estimates. Sustained demand for sleep devices, productivity gains and gross margin expansion drove growth.
Why it matters — RMD watchers may note the earnings and revenue beat alongside improved gross margin and continued sleep-device demand.
ResMed reported fiscal Q1 2027 revenue of $1.4 billion, up 6% year over year on a reported basis and 7% on a core constant-currency basis. Growth in sleep devices, masks and residential care software offset lower life-support device sales, while non-GAAP diluted EPS rose 14% to $2.91.
Why it matters — The results give RMD watchers an update on revenue growth, product-category performance and earnings per share.
The 21 Wall Street analysts covering ResMed, Inc. have a median 12-month price target of $270, with estimates ranging from $210 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering ResMed, Inc., 10 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ResMed, Inc. 85 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, ResMed, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +12.2% from the last close, and Ticker Nerd's factor model ranks ResMed, Inc. 85 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ResMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $210 to $320 over the next 12 months.
ResMed, Inc. returned -1.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Top 10 High Growth Dividend Stocks For November 2026". Seeking Alpha listed RMD among 10 high-quality dividend growth stocks for November 2026, using criteria that included consistent dividend growth, payout ratios below 100%, and stated future-return potential.
ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care. ResMed develops and markets cloud-connected medical devices, including positive airway pressure systems, masks, home ventilators, and related accessories used to diagnose and manage sleep apnea and other chronic respiratory disorders. The company also provides software and connected-care platforms that support home healthcare, post-acute care, and care coordination for providers, patients, and caregivers. Its product portfolio serves hospitals, sleep clinics, home medical equipment suppliers, and long-term care organizations across global markets. ResMed Inc. plays an important role in the healthcare market by combining medical devices with software to improve treatment delivery, patient monitoring, and care management in home and clinical settings.
CEO Mr. Michael J. Farrell BE, MBA, SM · 11,370 employees · United States · https://www.resmed.com
